Analysts expect that Jounce Therapeutics Inc (NASDAQ:JNCE) will post earnings of ($0.59) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Jounce Therapeutics’ earnings. The lowest EPS estimate is ($1.04) and the highest is ($0.22). Jounce Therapeutics posted earnings per share of $0.05 during the same quarter last year, which would indicate a negative year-over-year growth rate of 1,280%. The company is scheduled to report its next quarterly earnings report on Friday, March 9th.
According to Zacks, analysts expect that Jounce Therapeutics will report full-year earnings of ($0.86) per share for the current financial year, with EPS estimates ranging from ($1.29) to ($0.49). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.37) per share, with EPS estimates ranging from ($1.58) to ($1.15). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Jounce Therapeutics.
Jounce Therapeutics (NASDAQ:JNCE) last announced its quarterly earnings results on Monday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.12. Jounce Therapeutics had a negative return on equity of 1.39% and a negative net margin of 2.03%. The company had revenue of $18.10 million during the quarter, compared to analyst estimates of $20.00 million. The company’s revenue for the quarter was up 7.1% compared to the same quarter last year.
Jounce Therapeutics (JNCE) opened at $14.14 on Friday. Jounce Therapeutics has a 12-month low of $11.05 and a 12-month high of $29.29.
Several institutional investors have recently made changes to their positions in JNCE. TIAA CREF Investment Management LLC acquired a new stake in shares of Jounce Therapeutics in the first quarter valued at $229,000. Geode Capital Management LLC acquired a new stake in shares of Jounce Therapeutics during the first quarter worth $1,573,000. Goldman Sachs Group Inc. acquired a new stake in shares of Jounce Therapeutics during the first quarter worth $271,000. Strs Ohio raised its position in shares of Jounce Therapeutics by 1,863.2% during the second quarter. Strs Ohio now owns 37,300 shares of the company’s stock worth $523,000 after purchasing an additional 35,400 shares during the period. Finally, Schwab Charles Investment Management Inc. raised its position in shares of Jounce Therapeutics by 95.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 24,219 shares of the company’s stock worth $340,000 after purchasing an additional 11,833 shares during the period. Institutional investors and hedge funds own 47.55% of the company’s stock.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Jounce Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Jounce Therapeutics Inc and related companies.